The National Institute of General Medical Sciences (NIGMS) awarded Chromatan Inc. a $2,823,293 Project Grant (CFDA 93.859) on May 15, 2024 to commercialize its Continuous Countercurrent Tangential Chromatography (CCTC) platform for purification of recombinant adeno-associated virus (rAAV) vectors used in gene therapies. The project aims to develop a comprehensive process development toolkit, generate pilot-scale data for multiple rAAV serotypes, integrate capture and polishing operations, and demonstrate scale-up to 50-200 L cGMP manufacturing. This CCTC technology is designed to significantly improve recovery, product quality, and productivity compared to traditional column chromatography methods, addressing critical bottlenecks in downstream processing for the rapidly growing gene therapy industry.
Generated 3/4/25, 2:35 AM